UBS Group’s Zhengye Biotechnology Holding ZYBT Stock Holding History

UBS Group’s Portfolio ZYBT Stock Details ZYBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$5.04K	Sell	4,202 -3,790	-47%	-$5.81K	﹤0.01%	9582
2026 Q2	$5.41K	Sell	7,992 -44	-0.5%	-$39	﹤0.01%	8930
2026 Q1	$7.51K	Sell	8,036 -1,079	-12%	-$1.01K	﹤0.01%	8569
2025 Q4	$10.5K	Buy	9,115 +4,786	+111%	+$10.6K	﹤0.01%	8212
2025 Q3	$11.3K	Sell	4,329 -150,183	-97%	-$1.04M	﹤0.01%	8493
2025 Q2	$922K	Buy	154,512 +153,223	+11,887%	+$1.22M	﹤0.01%	5515
2025 Q1	$6.94K	Buy	+1,289	New	+$5.99K	﹤0.01%	8869

Other funds holding ZYBT

Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return

StoneX Group New York $2.75B AUM 24.13% 1-Year Est. Return

Caitong International Asset Management Hong Kong $1.04B AUM 150.26% 1-Year Est. Return

UBS Group's ZYBT Position: Q3 2026 in Review

UBS Group reduced its Zhengye Biotechnology Holding (ZYBT) stake by 47% in Q3 2026, selling an estimated $5.81K and leaving 4,202 shares worth $5.04K. The position accounts for ﹤0.01% of the portfolio, ranked #9582.

UBS Group first reported a position in ZYBT in Q1 2025 and has held it in 7 quarters since. The position peaked at $922K in Q2 2025. 4 funds tracked by Wall St. Rank hold ZYBT as of Q3 2026.

UBS Group held 4,202 shares of Zhengye Biotechnology Holding worth $5.04K as of Q3 2026.
UBS Group sold 3,790 Zhengye Biotechnology Holding shares in Q3 2026, an estimated $5.81K.
Zhengye Biotechnology Holding made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #9582 holding.
UBS Group first reported a position in Zhengye Biotechnology Holding in Q1 2025 and has held it in 7 quarters since.
UBS Group's Zhengye Biotechnology Holding position peaked at $922K in Q2 2025.
4 funds tracked by Wall St. Rank held Zhengye Biotechnology Holding as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.